<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250236</url>
  </required_header>
  <id_info>
    <org_study_id>Grueb Klin CT</org_study_id>
    <nct_id>NCT01250236</nct_id>
  </id_info>
  <brief_title>Effect of Brimonidine on Corneal Thickness</brief_title>
  <official_title>Effect of Brimonidine on Corneal Thickness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augenarztpraxis Breisach</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Augenarztpraxis Breisach</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brimonidine, an alpha-2 adrenoceptor agonist, is an effective and safe medication which is
      widely used in glaucoma treatment. Although it is known that it is quickly taken up by the
      cornea following topical administration and that the cornea has alpha-2 adrenoceptors there
      are only few studies available on the impact brimonidine has on the cornea. The aim of the
      study is to find out

        1. whether topical administration of brimonidine results in interaction with corneal
           alpha-2 adrenoceptors in terms of an increase in corneal thickness and

        2. whether there are any differences between the response corneal epithelium, stroma and
           endothelium show to alpha-2 adrenoceptor stimulation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>corneal thickness</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>intraocular pressure</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Impact of Brimonidine on the Cornea</condition>
  <arm_group>
    <arm_group_label>verum</arm_group_label>
    <description>brimonidine 0.1% eye drops twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <description>sodium hyaluronate 1.8mg/ml eye drops twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brimonidine 0.1%</intervention_name>
    <description>brimonidine 0.1% eye drops twice daily</description>
    <arm_group_label>verum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>sodium hyaluronate 1.8mg/ml eye drops twice daily</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        consecutive
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy, 18-99 years, normal ophthalmologic history, consent to participate in the
             study

        Exclusion Criteria:

          -  any serious medical or neurologic conditions and/or regular use of local or systemic
             medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Grueb, Priv. Doz. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Augenarztpraxis Breisach</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Grueb, Priv. Doz. Dr.</last_name>
    <phone>004976677766</phone>
    <email>matthias.grueb@web.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Augenarztpraxis</name>
      <address>
        <city>Breisach</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79206</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Grueb, Priv. Doz. Dr.</last_name>
      <phone>004976677766</phone>
      <email>matthias.grueb@web.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Grueb, Priv. Doz. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>November 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2010</study_first_posted>
  <last_update_submitted>December 2, 2010</last_update_submitted>
  <last_update_submitted_qc>December 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>PD Dr. Matthias Grueb</name_title>
    <organization>Augenarztpraxis Breisach</organization>
  </responsible_party>
  <keyword>brimonidine</keyword>
  <keyword>alpha-2 adrenoceptor</keyword>
  <keyword>cornea</keyword>
  <keyword>corneal thickness</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 4, 2011</submitted>
    <returned>August 1, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

